Alipogene tiparvovec

DB13521ApprovedGene Therapies

Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. It is being investigated for the...

Also known as: AAV1-LPL S447X · AAV1-LPL(S447X)
Code names: AMT-011

Resolves to

Compound

UNII20OK4AFR4YCAS929881-05-0KEGGD10843

Clinical / RWD

ATCC10AX10

Targets

P06858LPL

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 3 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alipogene tiparvovec, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account